The ATHENA human papillomavirus study: design, methods, and baseline results - 23/12/11
, Raymond Apple, PhD c, Toniann Derion, PhD c, Teresa L. Wright, MD c
Reprints: Catherine Behrens, MD, PhD, 4300 Hacienda Dr., Pleasanton, CA 94588Résumé |
Objective |
The objective of the study was to describe baseline data from Addressing the Need for Advanced HPV Diagnostics, a prospective, multicenter US cervical cancer screening trial.
Study Design |
A total of 47,208 women aged 21 years or older undergoing routine screening were enrolled; liquid-based cytology and human papillomavirus (HPV) testing were performed. Women with abnormal cytology underwent colposcopy, as did high-risk HPV (hrHPV)–positive women and a random subset of women negative by both tests aged 25 years or older. Verification bias adjustment was applied; 95% confidence intervals were computed by the bootstrap method.
Results |
The prevalence of cytologic abnormalities was 7.1%. hrHPV, HPV 16, and HPV 18 were detected using the cobas HPV Test in 12.6%, 2.8%, and 1.0% of women, respectively. Both cytologic abnormalities and hrHPV positivity declined with increasing age. The adjusted prevalence of cervical intraepithelial neoplasia grade 2 (CIN2) or greater in women aged 25-34 years was 2.3%, decreasing to 1.5% among older women.
Conclusion |
The Addressing the Need for Advanced HPV Diagnostics study provides important estimates of the prevalence of cytologic abnormalities, hrHPV positivity, and CIN2 or greater in a US screening population.
Le texte complet de cet article est disponible en PDF.Key words : Addressing the Need for Advanced HPV Diagnostics study, cervical cancer screening, cervical intraepithelial neoplasia, genotype, human papillomavirus deoxyribonucleic acid testing
Plan
| T.C.W. has been a consultant and speaker for Merck, GlaxoSmithKline, and Roche Molecular Systems and a consultant for Gen-Probe and Becton Dickenson. M.H.S. has been a consultant in clinical trial and HPV DNA test development for QIAGEN, Roche Molecular Systems, BD, Gen-Probe, Ventana, and Merck. C.M.B., R.A., T.D., and T.L.W. are employed by Roche Molecular Systems, the sponsor of the study. Victoria Tomlinson, Health Interactions, London, England, UK, provided editorial assistance in formatting and proofing of the final draft manuscript, funded by Roche Molecular Systems. |
|
| This study was supported in part by Roche Molecular Systems, Inc, Pleasanton, CA. |
|
| Cite this article as: Wright TC, Stoler MH, Behrens CM, et al. The ATHENA human papillomavirus study: design, methods, and baseline results. Am J Obstet Gynecol 2012;206:46.e1-11. |
Vol 206 - N° 1
P. 46.e1-46.e11 - janvier 2012 Retour au numéro
Article précédent
- Is ovarian volume estimation reliable when compared with true volume?
- Gurkan Bozdag, Mehmet Coskun Salman, Sezcan Mumusoglu, Zuhal Yapici, Serdar Gunalp
- Resuscitation of likely nonviable infants: a cost-utility analysis after the Born-Alive Infant Protection Act
- John Colin Partridge, Mya D. Sendowski, Alma M. Martinez, Aaron B. Caughey
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?